Compare BLD & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLD | GH |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | BLD | GH |
|---|---|---|
| Price | $550.90 | $104.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $444.14 | $102.81 |
| AVG Volume (30 Days) | 285.3K | ★ 2.0M |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 19.67 | N/A |
| Revenue | ★ $5,236,045,000.00 | $902,569,000.00 |
| Revenue This Year | $2.61 | $35.23 |
| Revenue Next Year | $13.86 | $27.38 |
| P/E Ratio | $28.01 | ★ N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $266.26 | $34.88 |
| 52 Week High | $555.85 | $120.74 |
| Indicator | BLD | GH |
|---|---|---|
| Relative Strength Index (RSI) | 72.31 | 46.49 |
| Support Level | $521.03 | $100.26 |
| Resistance Level | $555.85 | $108.51 |
| Average True Range (ATR) | 18.20 | 6.12 |
| MACD | 5.16 | -1.05 |
| Stochastic Oscillator | 94.78 | 34.64 |
TopBuild Corp is an installer and distributor of insulation products. Its operating segments involve the Installation and Specialty Distribution segment. The installation segment provides insulation installation services nationwide through contractor services business. Speciality Distribution segment distributes building and mechanical insulation, insulation accessories and other building product materials for the residential, commercial, and industrial end markets. The majority of revenue is earned from the installation segment. Its main customers are contractors. Other products include gutters, after-paint, garage doors, fireplaces, and fireproofing and stopping. TopBuild operates majorly in the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.